

Edgar Filing: ZONAGEN INC - Form 8-K

ZONAGEN INC
Form 8-K
June 29, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): JUNE 29, 2004

ZONAGEN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)

0-21198
(COMMISSION FILE NUMBER)

76-0233274
(I.R.S. EMPLOYER IDENTIFICATION NUMBER)

2408 TIMBERLOCH PLACE, SUITE B-1
THE WOODLANDS, TEXAS 77380
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)

(281) 719-3400
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)

ITEM 5. OTHER INFORMATION

On June 29, 2004, Zonagen, Inc. (the "Company") announced in a press release that it will initiate a European Phase I/II study of its lead program Progenta(TM) for the treatment of uterine fibroids.

A copy of the Company's press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

c. Exhibits

Exhibit Number	Description
99.1	Press Release dated June 29, 2004.

Edgar Filing: ZONAGEN INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZONAGEN, INC.

Date: June 29, 2004.

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.
Vice President, Business Development and
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number -----	Description -----
99.1	Press Release dated June 29, 2004.